ValuEngine upgraded shares of Zafgen (NASDAQ:ZFGN) from a strong sell rating to a sell rating in a research note released on Friday, February 2nd.
Separately, Zacks Investment Research cut shares of Zafgen from a buy rating to a hold rating in a report on Saturday, January 13th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and one has given a buy rating to the company’s stock. Zafgen has an average rating of Hold and an average price target of $6.63.
Zafgen (NASDAQ:ZFGN) traded up $0.24 during trading on Friday, hitting $8.37. 200,717 shares of the stock traded hands, compared to its average volume of 277,229. The company has a market capitalization of $230.08, a PE ratio of -4.62 and a beta of -0.51. Zafgen has a 52-week low of $3.21 and a 52-week high of $9.36.
Large investors have recently made changes to their positions in the stock. Two Sigma Investments LP grew its position in Zafgen by 91.1% in the fourth quarter. Two Sigma Investments LP now owns 61,048 shares of the biopharmaceutical company’s stock worth $282,000 after acquiring an additional 29,101 shares in the last quarter. GSA Capital Partners LLP purchased a new position in Zafgen in the second quarter worth $259,000. Bank of New York Mellon Corp grew its position in Zafgen by 139.1% in the fourth quarter. Bank of New York Mellon Corp now owns 87,571 shares of the biopharmaceutical company’s stock worth $405,000 after acquiring an additional 50,939 shares in the last quarter. OxFORD Asset Management LLP purchased a new position in Zafgen in the second quarter worth $364,000. Finally, Acadian Asset Management LLC grew its position in Zafgen by 18.3% in the fourth quarter. Acadian Asset Management LLC now owns 104,014 shares of the biopharmaceutical company’s stock worth $481,000 after acquiring an additional 16,072 shares in the last quarter. Institutional investors own 48.63% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Zafgen (ZFGN) Lifted to Sell at ValuEngine” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright legislation. The original version of this story can be accessed at https://www.dispatchtribunal.com/2018/02/18/zafgen-zfgn-upgraded-by-valuengine-to-sell.html.
Zafgen Company Profile
Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Zafgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen and related companies with MarketBeat.com's FREE daily email newsletter.